MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.
Also called NCT03234348
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 151 participants
- Registry
-
NCT03234348
-
- Main results
- Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial
- Other papers using this trial's data
- Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Spain
- Registry status
- Completed
Technical summary
Registry record NCT03234348. Randomized; double masking; primary purpose treatment. Start 2017-07-01 (actual); primary completion 2019-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction
- Acronym
- MAGSTEMI
- Condition
- Acute Coronary Syndrome
- Condition
- ST Segment Elevation Myocardial Infarction
- Condition
- Stent
- Intervention (Device)
- Percutaneous coronary intervention
- Lead sponsor
- Hospital Clinic of Barcelona
- Collaborator
- Spanish Society of Cardiology
Record details
- Record id
cardio:ct-nct03234348- Content hash
0a415512bbad9ed191c1a2e717cc19359d05578fa6940f817a56ad4ae653cbe4